Medigene AG: Medigene AG Amends Financial Guidance for 2024

Planegg/Martinsried (pta029/18.12.2024/19:45 UTC+1)

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today adjusted its financial guidance for fiscal year 2024.

The Company's financial guidance include potential future milestone payments from existing partnerships that are highly likely to materialize (see Annual Report 2023). As a milestone payment of EUR 2 million expected for 2024 is no longer anticipated to be received in the 2024 financial year, the Company has decided to amended its 2024 revenue guidance from previously EUR 9 - 11 million to EUR 7 - 9 million.

The Company maintains its guidance of a cash runway into July 2025 as it expects additional other income in 2025.

The Company maintains its guidance on expected R&D expenses in the range of EUR 11.5 -13.5 million (prior estimate of EUR 11-13 million amended in May 2025).

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A40ESG2 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate